10 news items
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
MNKD
8 May 24
-101 which may allow us to bring this innovative product to patients more quickly." Revenue Highlights
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD
6 May 24
(NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
MNKD
1 May 24
(NASDAQ:MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
MNKD
30 Apr 24
of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will proceed
MannKind Announces IND Clearance From US FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD
29 Apr 24
on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases
jo87i9aipd6fgqvvumbg
MNKD
29 Apr 24
(NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices
6577x250
MNKD
26 Mar 24
of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We
98p6lntt rydrhe0g3
MNKD
11 Mar 24
and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan
nirhjai 2pceewpyd4zki
MNKD
5 Mar 24
(NASDAQ:MNKD) focuses on the development and commercialization of innovative therapeutic products
cgg0cg
MNKD
4 Mar 24
on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine
- Prev
- 1
- Next